The current therapy on allergic inflammation is unsatisfactory. Probiotics improve the immunity in the body. This study aims to test a hypothesis that administration with Clostridium butyricum (C. butyricum) enforces the effect of specific immunotherapy (SIT) on intestinal allergic inflammation. In this study, an ovalbumin (OVA) specific allergic inflammation mouse model was created. The mice were treated with SIT or/and C. butyricum. The results showed that the intestinal allergic inflammation was only moderately alleviated by SIT, which was significantly enforced by a combination with C. butyricum; treating with C. butyricum alone did not show much inhibitory efficacy. The increase in the frequency of the interleukin (IL)-10-producing OVA-specific B cell (OVAsBC) was observed in mice in parallel to the inhibitory effect on the intestinal allergic inflammation. The in vitro treatment of the OVAsBCs with OVA increased the histone deacetylase-1 (HDAC1) phosphorylation, modulated the transcription of the Bcl6 gene, and triggered the OVAsBCs to differentiate to the IgE-producing plasma cells. Exposure to both OVA and butyrate sodium in the culture increased the expression of IL-10 in OVAsBCs. In conclusion, administration with C. butyricum enforces the inhibitory effect of SIT on allergic inflammation in the mouse intestine.
or further develop into plasma cells with the capacity to produce antigen specific IgE. Yet, the factors leading B cells to become plasma cells are not fully understood.
Specific immunotherapy (SIT) is the only specific remedy to treat allergen related inflammation in the body. SIT has demonstrated the ability to desensitize patients to specific food allergens, which involves administering gradually increasing doses of an allergen over time to induce immunologic changes 5 . The ultimate goal of SIT is to induce immune tolerance to specific allergens by inducing antigen specific immune regulatory cells, such as regulatory T cells (Treg) and regulatory B cells (Breg) 6 . Yet, SIT was shown to desensitize patients; however a long lasting effect of tolerance could not be shown 7 . Upon re-exposure to specific antigens, the Tregs and Bregs are activated to release immune suppressor mediators, such as IL-10 and transforming growth factor-β , to suppress other effector T cell activities, thus to inhibit the allergic inflammation 8 . However, the mechanism of generating antigen specific Tregs and Bregs has not been fully understood yet.
Probiotics are defined as "live microorganisms which, when administered in adequate amounts, confer a health benefit on the host" 9 . Published data suggest that administration of probiotics improves the intestinal immunity 10 . Probiotics may inhibit inflammation and/or activate innate immunity in the intestine, which can be used within therapeutic strategies to restore the host gut microbiota 11 . Probiotics contribute to the maintenance of the intestinal homeostasis via activating Toll like receptor 4 12 . It seems that probiotics benefit the host immunity; yet, the underlying mechanism remains to be further elucidated.
In this study, we treated mice with antigen specific allergic inflammation with SIT and one of the probiotic strains, the Clostridium butyricum (C. butyricum). The results showed that administration of C. butyricum markedly enforced the therapy of SIT on the antigen specific allergic inflammation in the intestine. The C. butyricum-derived butyrate regulated the signal transduction pathway of IgE production in antigen specific B cells and induced IL-10 expression.
Results
C. butyricum enforces the effect of SIT on intestinal allergic inflammation. The effect of SIT on food allergen related intestinal inflammation is to be improved 13 . Since probiotics can improve the intestinal immunity 10 , we inferred that probiotics might enforce the effect of SIT on intestinal allergic inflammation. To test the inference, a food allergy mouse model was developed. The allergic mice showed food allergy-like signs in the intestine. The mice were treated with SIT or/and C. butyricum. The results showed that SIT moderately improved the allergic inflammation in the intestine, which was markedly enforced by the addition of C. butyricum; while treatment with C. butyricum alone did not apparently inhibit the intestinal inflammation (Fig. 1) . In addition, grouped allergic mice were treated with LGG or SIT/LGG in the same procedures of administration with C. butyricum or SIT/C. butyricum. C. butyricum promotes therapeutic efficacy on allergic inflammation in the intestine. Food allergy mice were treated with the procedure as denoted on the X axis of the figures and in the text. The data of bars are presented as mean ± SD. *p < 0.01, compared with the "saline" group. $, p < 0.01, compared with SIT group. SIT: Specific immunotherapy. CB: C. butyricum (10 9 organisms/mouse/day by gavage).
LGG: Lactobacillus rhamnosus GG (10 9 organisms/mouse/day by gavage). #, IL-10-deficient mice. Each group n = 6. Samples from individual mice were processed separately. The results showed that administration with LGG did not apparently improve the allergic inflammation in the mice (Fig. 1) . The data suggest that using C. butyricum can enforce the effect of SIT on intestinal allergic inflammation.
C. butyricum plays an important role in the SIT-induced regulatory B cells. The data of Fig. 1 imply that the administration of SIT/C. butyricum might induce immune tolerant cells, such as Tregs or/ and Bregs, in the intestine. We next assessed the immune tolerant mediator TGF-β -and IL-10-positive cells in the isolated LPMCs. The results showed that the frequency of TGF-β positive cells was only slightly increased ( Fig. 2A-D) while the treatment with SIT/C. butyricum markedly increased the frequency of IL-10 positive cells in LPMCs, which did not occur in mice treated with either SIT alone or C. butyricum alone (Fig. 2E-H) . We also detected that more than 90% IL-10 + cells (Fig. 2H ) were CD19 positive (Fig. 2I) , The results indicate that administration of SIT/C. butyricum induces IL-10-producing B cells in the intestine of allergic mice.
Published data indicate that the IL-10 producing regulatory B cells play a critical role in the inhibition of non-IgE mediated food allergy 14 . We wondered if the IL-10-producing B cells were OVA-specific or vice versa. To this end, we isolated CD19 + B cells from LPMCs and analyzed by flow cytometry. The results showed that, after exposure to OVA in the culture, the B cells from the allergic mouse intestine proliferated markedly, including 31.4% in allergic mice treated with saline (the control), 31.1% in mice treated SIT and 36.1% in mice treated with C. butyricum and 33.4% in mice treated with SIT/C. butyricum ( Fig. 2J-N) . The results indicate the sensitization induces OVAsBCs in the intestine. We next assessed the IL-10 + B cells in the proliferated portion of the OVAsBCs. The results showed that about 50% IL-10 + B cells were detected in mice treated with SIT/C. butyricum, less than 10% of the IL-10 + B cells were detected in the rest three groups ( Fig. 2O-S) . The results indicate that treating allergic mice with SIT/C. butyricum induces IL-10 + producing B cells (Breg) in the mice. To test if the IL-10 from the Bregs played a critical role in the alleviation of the allergic inflammation in the intestine induced by SIT/C. butyricum, in separate experiments, IL-10-deficient mice were sensitized to OVA and treated with SIT/C. butyricum; the results showed that using IL-10-deficient mice abolished the therapeutic effect ( Fig. 1A-F ).
C. butyricum-derived butyrate switches the plasma cell differentiation of OVAsBC to Breg development. To take an insight into the mechanism by which SIT/C. butyricum converted OVAsBCs to Bregs in allergic mice, we assessed the effect of butyrate, a product of C. butyricum 15 , on the differentiation of OVAsBC. We isolated OVAsBC from the spleen of OVA-sensitized mice. The B cells were cultured with OVA (1 μ g/ml; the specific antigen) or/and butyrate sodium for 4 days. As shown by flow cytometry data, in the B cells exposed to OVA alone, a portion of the B cells became CD138 positive (Fig. 3A,B) , suggesting the OVAsBCs have differentiated into plasma cells. Exposure to butyrate alone did not induce either CD138
+ cells or IL-10 + B cells (Fig. 3C ). In those cells exposed to both OVA and butyrate, about 78.4% of the cells became IL-10 positive (Fig. 3D) . The results suggest that, in the presence of specific antigens, butyrate switches antigen specific B cells from the propensity of differentiation to plasma cells to the Breg development. To test the inference, we added Btk, an inhibitor of B cell receptor signal, to the culture in the presence of both OVA and butyrate. Indeed, the generation of IL-10 + B Butyrate inhibits HDAC1 activation and promotes Bcl6 expression in OVAsBCs. The data in Fig. 3 suggest that butyrate plays an important role in the conversion of OVAsBC to Bregs during SIT. Since butyrate is an inhibitor of HDAC1 16 , HDAC1 might be involved in Breg generation induced by OVA/butyrate in Fig. 3 . To test the inference, we assessed the HDAC1 phosphorylation in the OVAsBCs after exposure to OVA. The results showed that exposure to OVA markedly increased the HDAC1 phosphorylation (Fig. 4A) . We also detected a complex of pHDAC1 and PU.1 (the transcription factor of Bcl6) in the OVAsBCs (Fig. 4B) . After exposure to OVA, this complex bound the Bcl6 promoter (Fig. 4C ) and reduced the Bcl6 gene transcription, which was prevented by the presence of butyrate sodium (Fig. 4D,E) . The results suggest that exposure to a specific antigen can induce activation of HDAC1, which is associated with the suppression of Bcl6 expression in OVAsBCs, and did not occur when the OVA was replaced by bovine serum albumin (data not shown). The data imply that the B cell receptor (BCR) activation is involved in the specific antigen-suppressed Bcl6 expression in OVAsBCs. To test the inference, we added a BCR signal blocker, Bruton's tyrosine kinase (Btk) blocker, to the culture medium. OVA-induced Bcl6 suppression was abolished (Fig. 4A,D,E) .
The above results implicate that Bcl6 may be the molecule related to the expression of IL-10 in OVAsBCs after treating with OVA and butyrate. To test the hypothesis, we overexpressed Bcl6 in OVAsBCs (Fig. 5A) . After exposure to OVA in the culture for 4 days, the Bcl6 overexpressing OVAsBCs showed the ability to produce IL-10 ( Fig. 5B,C) while the IgE production is below the detectable levels (Fig. 5D,E) .
Discussion
To suppress the allergic inflammation is of significance in the alleviation of the food allergen related intestinal diseases, such as food allergy. The present data suggest that the combination of SIT and C. butyricum resulted in a much better inhibitory effect on OVA-specific allergic inflammation in the mouse intestine than using either SIT alone or C. butyricum alone. The treatment also induced OVA-specific IL-10-producing B cells (Breg) in the intestine.
SIT is the only specific therapeutic remedy for allergic diseases currently. The efficiency of SIT is supposed to be improved. The present data showed although the SIT alone did suppress the Th2 response in the mice, the clinical symptoms, including the drop in core temperature and diarrhea, were not appreciably improved. The results are consistent with the report from Dr. Berin's laboratory 13 . Based on published data that using specific probiotic strains can alleviate allergic disorders 17 , we combined SIT and C. butyricum in the treatment of food allergy mice. Such a strategy markedly enhanced the therapeutic effect on the allergic inflammation in the intestine. It is to be noted that utilizing C. butyricum alone did not apparently alleviate the allergic inflammation in the intestine as observed in the present study. Similar results were reported by Kukkonen et al. that probiotic treatment did not reduce the incidence of IgE-associated diseases in children 18 . Not much positive therapeutic outcome induced by oral supplementation with probiotics alone has been reported 19, 20 . The present data shed new light on the treatment of food allergy by a combination of SIT with C. butyricum, which significantly inhibited food allergen related inflammation in the mouse intestine. A fraction of IL-10-producing antigen specific Breg was detected in the intestine of mice treated with SIT/C. butyricum. The results suggest that the therapeutic effect may be generated by IL-10. Data obtained from the experiments using IL-10-deficient mice further support our hypothesis that IL-10 plays an essential role in the generation of this therapeutic effect. Previous reports also showed that IL-10-producing B cells played a critical role in suppressing the non-IgE mediated milk allergy 14 . Antigen specific B cells can differentiate to either IgE-producing plasma cells, or Bregs. Thus, to elucidate the mediating factors is of significance. The present in vitro results showed that exposure to specific antigens in the culture drove OVAsBCs to differentiate into the IgE-producing plasma cells while exposure to OVA/butyrate induced Bregs. The results suggest that butyrate plays a critical role in the induction of Bregs. Since using butyrate alone did not show the ability to convert OVAsBCs to Bregs, the conversion must have been satisfied by additional factors. Indeed, activation of BCR is also needed in the conversion of Bregs. The data are enforced by inhibiting the BCR signal in the presence of OVA/butyrate, in which the signal transduction pathway was disrupted by the presence of Btk, a blocker of BCR signal.
HDAC1 is one of the enzymes in regulating gene transcription 21 . We found that, upon exposure to the specific antigen OVA, HDAC1 was activated and formed a complex with PU.1, a transcription factor of Bcl6; the complex bound to the Bcl6 promoter and inhibited the Bcl6 gene transcription. Bcl6 has the immune tolerogenic ability 22 . The data suggest that because of the suppression of Bcl6, the OVAsBCs differentiated to IgE-producing plasma cells. The subsequent data supported this inference by showing that overexpression of Bcl6 markedly increased the expression of IL-10 in the OVAsBCs.
In addition to administration with C. butyricum, we also observed the effect of LGG on the allergic inflammation in the intestine. The results showed that administration with LGG did not show improvement on the allergic inflammation. Previous reports indicate that probiotics prevent respiratory tract infections and the conventional protection against GI infections 23 ; however, the effect of probiotics on food allergy has not been well defined yet. It was reported that probiotic treatment compared with placebo showed no effect on the cumulative incidence of allergic diseases 18 ; Rose et al. reported that in young children with recurrent wheeze and an atopic family history, oral LGG had no clinical effect on atopic dermatitis or asthma-related events, and only mild effects on allergic sensitization 24 , although probiotics were somewhat effective in preventing dermatitis 25 . Apart from Bregs, Tregs are also a major type of immune regulatory cells in the body. Type 1 regulatory T (Tr1) cells also produce IL-10. Whether the administration of SIT and C. butyricum also up regulates the development of Tr1 cells in the body is an interesting topic and worth being further investigated.
One of the drawbacks of the oral immunotherapy is the therapeutic effect cannot be lasted long 7 . Whether administration of C. butyricum can solve this shortcoming is worth being further investigated. In summary, the present data suggest that a combination of SIT with C. butyricum significantly enforces the therapeutic effect on inhibiting the food allergen related inflammation in the intestine, which can be a novel approach for the treatment of food allergy.
Materials and Methods
Reagents. The antibodies of HDAC1, pHDAC1, pPU.1, Bcl6 and IgE were purchased from Proteintech (Wuhan, China). ELISA kits of OVA-specific IgE, IL-4 and IL-13, and the fluorochrome-labeled antibodies of IL-10 and IgE were purchased from Biomart (Shanghai, China). Protein G, chromatin immunoprecipitation kit, a biotinylation kit, Butyrate sodium and ovalbumin (OVA) were purchased from Sigma Aldrich (Shanghai, China). PCI-32765 was purchased from Chem Blink (Shanghai, China). The reagents for real time RT-PCR and Western blotting were purchased from Invitrogen (Shanghai, China). Magnetic bead-conjugated streptavidin and immune cell isolation kits were purchased from Miltenyi Biotech (Shanghai, China). The endotoxin levels in all reagents were detected using the Limulus assay (Limulus amebocyte lysate QCL 1000, Bio Whittaker, Walkersville, MD, USA). The reagents used in this study contained < 0.2U endotoxin/10 μ g reagents.
Mice. BALB/c mice and IL-10-deficient mice (6-8 weeks old) were purchased from Shanghai Xinmao Experimental Animal Center (Shanghai, China). The mice were maintained in a pathogen-free environment and allowed to access food and water freely. The using mouse in the present study was approved by the Animal Ethic Committee at Shenzhen University. The methods were carried out in "accordance" with the approved guidelines.
Development of food allergy mouse model. Following our established procedures 26 , a mouse model of intestinal allergic inflammation was developed. Briefly, Mice were gavage-fed with OVA (1 mg/mouse) and cholera toxin (20 μ g/mouse) in 0.3 ml saline once a week for 4 weeks. The mice were challenged with OVA (5 mg/mouse) via gavage on week 5 and sacrificed the next day. The assessment of food allergic inflammation in the mice was carried out following our established procedures that were published previously 27, 28 . 29 , the sensitized mice were treated with oral SIT commencing one week after the last gavage with cholera toxin/OVA for two weeks. Briefly, the OVA was gavage-fed with the doses of 1 mg (days 1 and 2), 5 mg (days 3 and 4), 10 mg (days 5-7), 25 mg (days 8 and 9), and 50 mg (days [10] [11] [12] [13] [14] . The OVA was administrated with or without mixing with probiotics (see below).
Specific immunotherapy (SIT). Following our established procedures

Treatment with probiotics. C. butyricum (the Shenzhen Kexing Biotech; Shenzhen, China) and
Lactobacillus rhamnosus GG (LGG; ATCC; Beijing, China) were cultured in BHI medium for 16 h at 37 °C on the day before the experiments. The probiotics were centrifuged at 3000 rpm for 5 min, 10 9 organisms resuspended in 500 μ L PBS (pH 7.4). Either of the probiotics were introduced into the stomach of mice daily using a gavage tube attached to a syringe daily commencing one week after the last gavage with cholera toxin/OVA.
Construction of an Ag-specific Tetramer. To isolate the OVAsBCs, a tetramer was constructed following our established procedures 26 . Briefly, the biotinylated OVA was incubated with magnetic particle-conjugated streptavidin for 30 min at room temperature. Unconjugated reagents less than 10 kDa were filtered through a filter tube by centrifugation. The OVA tetramers were collected for OVAsBC isolation.
OVAsBC Isolation. Following our established procedures 29, 30 , lamina propria mononuclear cells (LPMC) were isolated. and OVA tetramer was added to the LPMCs at 2 μ g/ml. The cells were incubated for 30 min and then passed through the columns in the magnetic apparatus provided by Miltenyi Biotech. Cells were collected, washed with acidic phosphate-buffered saline (PBS) (pH 3) to remove the bound OVA on the cell surface, and transferred to RPMI 1640 media for further experiments.
Assessment of OVAsBC proliferation. The isolated OVAsBCs were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) and cultured in the presence of OVA (1 μ g/ml; the specific Ag) and 2.5 μ g/ml anti-CD40 for 3 days. The frequency of CFSE positive cells was assessed by flow cytometry using the CFSE dilution assay. Western blotting. Total proteins were extracted, fractioned by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis), and transferred onto a PVDF membrane. After blocking with 5% skim milk for 30 min, the membrane was incubated with the primary antibodies overnight at 4 °C, and followed by incubating with the second antibodies (labeled by peroxidase) for 1 h at room temperature. Washing with TBST (Tris-buffered saline Tween 20) was performed after each incubation. The membrane was incubated with ECL (enhanced chemiluminescence). The results were photographed with a chemiluminescence gel imaging system (UVI, Beijing, China).
Quantitative real-time RT-PCR (RT-qPCR).
The total RNA was isolated with the TRIzol reagent. A cDNA was synthesized using a reverse transcription kit. PCR was performed in a qPCR device (MiniOpticon, Bio Rad) with the SYBR green PCR Master Mix. The cycle time values of the genes of interest were first normalized with β -actin of the same sample, and then the relative difference between control and each treatment group was calculated and expressed as a relative value. Primers using in the present study include: Bcl6 (acaccaccagcctcttatcc and ggcgagtagatgttgctgtg), IL-10 (ggtgagaagctgaagaccct and tgtctaggtcctggagtcca), IgE (atccagacagtgtgaagggg and tgactgaggttccttgaccc) and β -actin (gtgggaatgggtcagaagga and tcatcttttcacggttggcc).
Immunoprecipitation. The complexes of pHDAC1 and pPU.1 was detected with immunoprecipitation. For the pre-clearing, the cellular extracts were incubated with protein-G beads for 2 h, and centrifuged for 2 min at 2000 rpm. The supernatant was incubated overnight with anti-pPU.1 or anti-pHDAC1 antibody and protein-G beads. The immunoprecipitates were collected and washed with RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM Na3VO4, 1 mM NaF and protease inhibitors) and then subjected to Western blotting.
Chromatin immunoprecipitation (ChIP).
ChIP was performed according to the protocol described previously 31 . OVAsBC extracts were cross-linked with formaldehyde and sonicated. Resulting cell lysates (input) were immunoprecipitated with the respective antibodies (2.5 μ g each) of interest. The precipitated protein-DNA complexes were subjected to proteinase treatment. The primers used to confirm the binding of factors to the promoter region of Bcl6 were: Forward, gggttcttagaagtggtgatgc; reverse, cagcaacagcaataatcacctg.
BcL6 overexpression. The Bcl6 DNA vector was constructed by GeneScript (Nanjing, China). Statistics. The data are presented as mean ± SD. The difference between two groups was determined by Student t test or ANOVA if more than three groups. A p < 0.05 was set as a significant criterion.
